639 patents
Utility
Combinatorial Drug Delivery Device
11 Jan 24
In one aspect, a combinatorial drug delivery device is provided for delivering a predetermined selection of drug components.
Martin John McLoughlin, Chester Larrow, Mariano Mumpower
Filed: 23 Sep 23
Utility
Methods of Treating Colon Cancer Using Nanoparticle Mtor Inhibitor Combination Therapy
11 Jan 24
The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).
Neil P. DESAI
Filed: 13 Apr 23
Utility
Antibody Compositions and Methods of Use Thereof
4 Jan 24
The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants.
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Filed: 21 Aug 23
Utility
Sulfone Pyridine Alkyl Amide-substituted Heteroaryl Compounds
4 Jan 24
CHUNJIAN LIU, MICHAEL G. YANG, ZILI XIAO, LING CHEN, RYAN M. MOSLIN, JOHN S. TOKARSKI, DAVID S. WEINSTEIN, STEPHEN T. WROBLESKI
Filed: 5 Sep 23
Utility
Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling
4 Jan 24
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway.
John P. COGSWELL, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
Filed: 2 Nov 22
Utility
Dosing and Administration of Non-fucosylated ANTI-CTLA-4 Antibody As Monotherapy
4 Jan 24
The present invention provides methods of dosing and administration of non-fucosylated anti-CTLA-4 antibodies, such as non-fucosylated ipilimumab, as monotherapy, and related compositions and dosage forms.
Leonard P. JAMES, Yougan CHENG, Brian J. SCHMDIT, John J. ENGELHARDT, Li LI
Filed: 5 Nov 21
Utility
Modified Fibroblast Growth Factor 21 (FGF-21) for Use In Methods for Treating Nonalcoholic Steatohepatitis (Nash)
28 Dec 23
Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH.
Edgar Davidson CHARLES, III, Rose C. CHRISTIAN, Yi LUO
Filed: 31 Mar 23
Utility
Process Toward the Manufacture of (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE
28 Dec 23
Subha MUKHERJEE, William P. GALLAGHER, Christopher Robert JAMISON, Carolyn S. WEI, Sergei KOLOTUCHIN, Amarjit SINGH, Nicolas CUNIERE, Chris SFOUGGATAKIS, Adrian ORTIZ, Steven R. WISNIEWSKI, Bin ZHENG, Helen Y. LUO, Sébastien François Emmanuel LEMAIRE, Cyril BEN HAÏM, Kostiantyn CHERNICHENKO, Diego Fernando Domenico BROGGINI, Simon Albert WAGSCHAL, Duy Chi Trung CAO, Karl REUTER, Björn SCHMALZBAUER, Philipp KOSCHKER, Martin D. EASTGATE, Dimitri SKLIAR, Alexander ZHDANKO, Christos XIOURAS, Matthew Penfield MOWER, Ngoc Duc TRAN, Ramdane RAHMANI, Xavier Jean-Marie JUSSEAU, Kiran MATCHA, Luca Alessandro PEREGO
Filed: 11 Oct 21
Utility
Methods of Redirecting of IL-2 to Target Cells of Interest
28 Dec 23
The present disclosure provides constructs comprising an anti-PDI antibody, or an alternative targeting moiety, fused to CD25 or an IL-2 binding fragment of CD25.
Flavio SCHWARZ, Xiaodi DENG, Pavel STROP
Filed: 12 Aug 21
Utility
Treatment of Cancer with Anti-gitr Agonist Antibodies
28 Dec 23
Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody.
Suba KRISHNAN, Penny E. PHILLIPS, Zheng YANG, Haiqing WANG
Filed: 12 Apr 23
Utility
Medical Imaging Analysis Using Self-supervised Learning
21 Dec 23
A method includes obtaining a first training data set including unannotated multi-dimensional medical images and executing a self-supervised masked image modeling (MIM) training process to pre-train an image encoder on the first training data set.
Zekai Chen, Kevin Alex Brown
Filed: 20 Apr 23
Utility
Miniaturized Dystrophins Having Spectrin Fusion Domains and Uses Thereof
21 Dec 23
Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin.
Glen B. Banks, Jonathan Harry Davis, Paul Charles Levesque
Filed: 2 Nov 22
Utility
Classifying Pharmacovigilance Documents Using Image Analysis
21 Dec 23
Provided herein are systems, apparatus, device, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for classifying a document using image analysis.
Sameen Mayur Desai
Filed: 28 Aug 23
Utility
Carbamoyloxymethyl Triazole Cyclohexyl Acids As
Lpa Antagonists
7 Dec 23
Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
Filed: 22 Aug 23
Utility
Method of Purity Determination by Capillary Electrophoresis
7 Dec 23
This disclosure provides protein separation techniques using detergents that have alkyl chains longer than 12 carbon atoms, which improves protein separation during electrophoresis.
Jeff W BECKMAN, Qian GUAN
Filed: 25 May 23
Utility
Antibodies Against TIM3 and Uses Thereof
30 Nov 23
Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein.
Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
Filed: 27 Feb 23
Utility
Methods for Concentrating Proteins
23 Nov 23
Provided herein are optimized methods for concentrating large volumes of antibody feedstocks to generate concentrated drug substances by ultrafiltration in a batch-like mode using a fed-batch setup.
Jessica Joy HUNG, Melissa Ann HOLSTEIN, Shing Fung LAM, Sanchayita GHOSE
Filed: 4 Oct 21
Utility
Aminoimidazole FPR2 Agonists
23 Nov 23
Heidi Perez, James A. Johnson, Sunita V. Dewnani
Filed: 8 Oct 21
Utility
Dimeric Milla Immunomodulators
23 Nov 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG
Filed: 8 Oct 21
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations, Anti-tigit Antibodies, and ANTI-PD-1 Antibodies
16 Nov 23
The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
Filed: 30 Sep 21